González-Fernández Á - Search Results

1

Nanoparticles and trained immunity: Glimpse into the future.

Magadán S, Mikelez-Alonso I, Borrego F, González-Fernández Á. Magadán S, et al. Adv Drug Deliv Rev. 2021 Aug;175:113821. doi: 10.1016/j.addr.2021.05.031. Epub 2021 Jun 2. Adv Drug Deliv Rev. 2021. PMID: 34087325 Free article. Review.

2

Natural killer (NK) cell-based immunotherapies and the many faces of NK cell memory: A look into how nanoparticles enhance NK cell activity.

Mikelez-Alonso I, Magadán S, González-Fernández Á, Borrego F. Mikelez-Alonso I, et al. Adv Drug Deliv Rev. 2021 Sep;176:113860. doi: 10.1016/j.addr.2021.113860. Epub 2021 Jul 5. Adv Drug Deliv Rev. 2021. PMID: 34237404 Review.

3

Human immunology and immunotherapy: main achievements and challenges.

Varadé J, Magadán S, González-Fernández Á. Varadé J, et al. Cell Mol Immunol. 2021 Apr;18(4):805-828. doi: 10.1038/s41423-020-00530-6. Epub 2020 Sep 2. Cell Mol Immunol. 2021. PMID: 32879472 Free PMC article. Review.

4

Assessing methods for blood cell cytotoxic responses to inorganic nanoparticles and nanoparticle aggregates.

Díaz B, Sánchez-Espinel C, Arruebo M, Faro J, de Miguel E, Magadán S, Yagüe C, Fernández-Pacheco R, Ibarra MR, Santamaría J, González-Fernández A. Díaz B, et al. Small. 2008 Nov;4(11):2025-34. doi: 10.1002/smll.200800199. Small. 2008. PMID: 18855973

5

Molecular characterization of B-cell epitopes for the major fish allergen, parvalbumin, by shotgun proteomics, protein-based bioinformatics and IgE-reactive approaches.

Carrera M, González-Fernández Á, Magadán S, Mateos J, Pedrós L, Medina I, Gallardo JM. Carrera M, et al. J Proteomics. 2019 May 30;200:123-133. doi: 10.1016/j.jprot.2019.04.005. Epub 2019 Apr 8. J Proteomics. 2019. PMID: 30974223

6

Generation of a human IgM monoclonal antibody directed against HLA class II molecules: a potential agent in the treatment of haematological malignancies.

Díaz B, Sanjuan I, Gambón F, Loureiro C, Magadán S, González-Fernández A. Díaz B, et al. Cancer Immunol Immunother. 2009 Mar;58(3):351-60. doi: 10.1007/s00262-008-0558-6. Epub 2008 Aug 2. Cancer Immunol Immunother. 2009. PMID: 18677479 Free PMC article.

7

The use of transgenic mice for the production of a human monoclonal antibody specific for human CD69 antigen.

Molina A, Valladares M, Magadán S, Sancho D, Viedma F, Sanjuan I, Gambón F, Sánchez-Madrid F, González-Fernández A. Molina A, et al. J Immunol Methods. 2003 Nov;282(1-2):147-58. doi: 10.1016/j.jim.2003.08.007. J Immunol Methods. 2003. PMID: 14604548

8

Rearrangement of only one human IGHV gene is sufficient to generate a wide repertoire of antigen specific antibody responses in transgenic mice.

Suárez E, Magadán S, Sanjuán I, Valladares M, Molina A, Gambón F, Díaz-Espada F, González-Fernández A. Suárez E, et al. Mol Immunol. 2006 Apr;43(11):1827-35. doi: 10.1016/j.molimm.2005.10.015. Epub 2005 Dec 15. Mol Immunol. 2006. PMID: 16343622

9

Polymeric nanostructure vaccines: applications and challenges.

Simón-Vázquez R, Peleteiro M, González-Fernández Á. Simón-Vázquez R, et al. Expert Opin Drug Deliv. 2020 Jul;17(7):1007-1023. doi: 10.1080/17425247.2020.1776259. Epub 2020 Jun 10. Expert Opin Drug Deliv. 2020. PMID: 32476491 Review.

10

Editorial to "Journey into the immunological properties of engineered nanomaterials: There and back again".

Dobrovolskaia MA, Afonin KA, González-Fernández Á. Dobrovolskaia MA, et al. Adv Drug Deliv Rev. 2022 Feb;181:114100. doi: 10.1016/j.addr.2021.114100. Epub 2021 Dec 23. Adv Drug Deliv Rev. 2022. PMID: 34954314 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

209 results

Search Page

Filters